Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

ESMO 2020 Highlights With Aditya Bardia, MD, MPH

October 29th 2020

Aditya Bardia, MD, MPH, discusses the results of the ASCENT trial in triple-negative breast cancer.

Beat AML Master Clinical Trial Showcases Paradigm Shift With Precision Medicine

October 28th 2020

Delaying treatment for up to 7 days so that genomic data can be utilized to inform a personalized treatment approach is safe, feasible, and can improve overall survival in patients with acute myeloid leukemia.

Role of Trop-2 as an Actionable Biomarker in Solid Tumors

October 28th 2020

Trophoblast cell surface antigen 2 is a glycoprotein that spans the epithelial membrane surface and plays a role in cell self-renewal, proliferation, and transformation.

FDA Approves FoundationOne Liquid CDx For New Indications in Advanced Ovarian, Breast, and NSCLC

October 27th 2020

The FDA has approved the FoundationOne Liquid CDx for use as a companion diagnostic for 3 targeted therapies: alpelisib in advanced or metastatic breast cancer, rucaparib in advanced ovarian cancer, and alectinib in a specific type of metastatic non–small cell lung cancer.

Next-Generation BRAF Inhibitor Plus Cobicistat Elicits Encouraging Activity in BRAF+ Refractory Solid Tumors

October 26th 2020

PLX8394, a next-generation BRAF inhibitor, in combination with cobicistat was found to demonstrate encouraging clinical activity with an acceptable safety profile in patients with BRAF-mutated, refractory solid tumors.

FDA Approves FoundationOne CDx for Larotrectinib in NTRK+ Tumors

October 23rd 2020

The FDA has approved the FoundationOne CDx comprehensive genomic test as a companion diagnostic for larotrectinib (Vitrakvi) to identify patients with NTRK1/2/3 gene fusions across all solid tumors.

MD Anderson and Taiho Pharmaceutical Collaborate to Develop Therapies for Brain Metastases

October 23rd 2020

The University of Texas MD Anderson Cancer Center and Taiho Pharmaceutical have formed a collaboration to do preclinical and early clinical research on potential therapies to treat brain metastases and those with cancers refractory to available therapies.

Subbiah Addresses Controversy Surrounding Pembrolizumab Approval for TMB-High Tumors

October 22nd 2020

In a special episode of OncLive On AirTM Vivek Subbiah, MD, discusses the FDA approval of pembrolizumab in TMB-high solid tumors and addressed the controversy surrounding the approval.

Novel Strategies for Targeting the “Guardian of the Genome” Emerge

October 22nd 2020

p53 presents a significant challenge for investigators, and the field is littered with clinical trial failures and abandoned drug development programs.

IDE196/Crizotinib Combo Under Exploration in GNAQ/11+ Solid Tumors

October 18th 2020

An ongoing, collaborative clinical trial has been expanded to evaluate the investigational protein kinase C inhibitor IDE196 in combination with the multikinase inhibitor crizotinib (Xalkori) for patients with GNAQ- or GNA11-mutated solid tumors, including metastatic uveal melanoma , skin melanoma, lung cancer, and colorectal cancer.

Garcia-Manero Previews Potential Therapeutic Standards in TP53-Mutated MDS/AML

October 15th 2020

In our exclusive interview, Guillermo Garcia-Manero, MD, discusses the prevalence of TP53 mutations in myelodysplastic syndromes and acute myeloid leukemia, the prognosis these mutations confer, and the development of eprenetapopt and magrolimab in this patient population.

COVID-19 Raises the Stakes of Preventive Medicine in Oncology

October 13th 2020

Anna Giuliano, PhD, discusses the work efforts to advance the reach of preventive vaccines and cancers, and the challenges researchers are facing in the process.

Gutierrez Provides Insight on Bridging Gaps in Cancer Care

October 12th 2020

In our exclusive interview, Rodolfo Gutierrez, MD, discusses the issues that surround access to care and clinical outcomes with Hispanic patients, efforts The Angeles Clinic has spearheaded to bridge this gap in care, and the importance of patient and provider education and awareness.

Family History Plays Key Role in Germline Testing for Hereditary Breast and Ovarian Cancers

October 12th 2020

Sofia D. Merajver, MD, PhD, discusses the importance of germline testing in patients with breast and ovarian cancer along with how this testing is being used to personalize treatment.

Identifying Genetic Variants, Matching With Targeted Therapies Serve as Next Great Challenge With Germline Testing in Oncology

October 12th 2020

Goutham Narla, MD, PhD, discusses the revolution of genetic testing and how it has led to more accurate and widespread assays for patients with cancer.

Patient Advocacy and Education Are Essential for Optimal Cancer Care

October 11th 2020

Caroline Farrington, PhD, shares her insight as both a researcher and a cancer survivor on the importance of patient advocacy, as well as the proper resources to aid patients through a cancer diagnosis.

Focusing on the Future of Genetic Testing in Oncology

October 10th 2020

John M. Carethers, MD, MACP, discusses recent developments in multi-gene panel testing.

Dr. Yap on the Rationale for the SEASTAR Trial in Advanced Solid Tumors

October 8th 2020

Timothy Yap, MBBS, PhD, FRCP, discusses the rationale for the ongoing phase 1b/2 SEASTAR trial in advanced solid tumors.

Subbiah Tempers Concerns Regarding Pembrolizumab Approval in TMB-High Solid Tumors

October 8th 2020

In our exclusive interview, Vivek Subbiah, MD, discusses the FDA approval of pembrolizumab in tumor mutational burden–high solid tumors, shares the “transformative importance” of the regulatory decision, and speaks to the controversy surrounding the approval.

Mobocertinib Continues to Show Clinical Activity in EGFR Exon 20–Mutant NSCLC

October 5th 2020

Mobocertinib elicited a 43% objective response rate and an 86% disease control rate in select patients with non–small cell lung cancer who have EGFR exon 20 insertion mutations.